Ausgewählte Publikationen
• The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus.
Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P.
Arch Phys Med Rehabil. 2005;86(8):1527-33

• Strength and endurance training lead to different post exercise glucose profiles in diabetic patients using a continuous subcutaneous glucose monitoring system
Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P. Eur J Clin
Invest. 2005 Dec;35(12):745-51.

• Continuous Glucose Monitoring in Diabetic Long Distance Runners
Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Kostner K, Dunky A, Haber P.
Int J Sports Med. 2005 Nov;26(9):774-80

• Mutations of the HFE gene in patients with hepatocellular carcinoma.
Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schoniger-Hekele M, Hackl F, Polli C, Rasoul-Rockenschaub S, Muller C, Wrba F, Gangl A, Ferenci P.
Am J Gastroenterol. 2003;98(2):442-7.

• Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin.
Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P.
J Hepatol. 1997;27(2):358-62.

• Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function.
Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrmann W, Kostner K.
Nephrol Dial Transplant. 2003;18(8):1568-72.

• HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis.
Cauza E, Hanusch-Enserer U, Etemad M, Koller M, Kostner K, Georg P, Dunky A, Ferenci P.
Clin Exp Rheumatol. 2005;23(1):7-12.

• Increased C282Y heterozygosity in gestational diabetes.
Cauza E, Hanusch-Enserer U, Bischof M, Spak M, Kostner K, Tammaa A, Dunky A, Ferenci P.
Fetal Diagn Ther. 2005 ;20(5):349-54.

• Distribution of patients with Wilson disease carrying the H1069Q mutation in Austria.
Cauza E, Ulrich-Pur H, Polli C, Gangl A, Ferenci P.
Wien Klin Wochenschr. 2000 7;112(13):576-9.

• Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.
Rheumatol Int. 2002;22(6):227-32.

• Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K.
Wien Klin Wochenschr. 2002 30;114(23-24):1004-7.

• Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A.
J Clin Pharm Ther. 2004;29(5):431-6

• Effects of LDL-immunoapheresis on plasma concentrations of vitamin E and carotenoids in patients with familial hypercholesterolemia.
Cauza E, Jansen M, Resch U, Dunky A, Derfler K, Winklhofer-Roob BM, Kostner K. J Clin Apher. 2004;19(4):174-9.

• Short-term Infliximab therapy improves symptoms of Psoriatic Arthritis and decreases concentrations of cartilage oligomeric matrix protein.
Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K. J Clin
Pharm Ther. 2006 Apr;31(2):149-52

• The Benefits of Long Term Exercise in Type 2 Diabetes Patients.
Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P.
Wien Med Wochenschr. 2006 Sep;156(17-18):515-9

• The benefit of strength training on arterial blood pressure in patients with type 2 diabetes mellitus measured with ambulatory 24-hour blood pressure systems
Barbara Strasser, Paul Haber, Christoph Strehblow and Edmund Cauza
Wien Med Wochenschr (2008) 158/13–14: 379–384

• Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding.
Hanusch-Enserer U, Cauza E, Brabant G, Dunky A, Rosen H, Pacini G, Tuchler H, Prager R, Roden M.
J Clin Endocrinol Metab. 2004;89(7):3352-8.

•Improvement of insulin resistance and early atherosclerosis in patients after gastric banding.
Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R.
Obes Res. 2004;12(2):284-91.

• Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding.
Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM.
Int J Obes Relat Metab Disord. 2003;27(3):355-61.

• Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese.
Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mahr B, Dunky A, Rosen HR, Koller U, Prager R. ObesRes. 2003;11(6):695-8.

Reviews
• Methotrexate therapy in rheumatologic diseases - an update
Cauza E, Dunky A.
Wien Med Wochenschr. 2003;153(13-14):291-4.

• HDL-therapy: the next big step in the treatment of atherosclerosis?
Kostner K, Cauza E.
Future Med Nov 2005; Vol. 1, 6, 767-773

• Psoriasis Arthritis
Cauza E, Dunky A.
Wien Med Wochenschr. 2006 Nov;156(21-22):587